VRTX Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Vertex Pharmaceuticals Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 401.08 USD 0.23%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast VRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRTX is 474.73 USD with a low forecast of 328.25 USD and a high forecast of 602.7 USD.

VRTX Lowest Forecast

Wall Street Target

VRTX Average Forecast

Wall Street Target

VRTX Highest Forecast

Wall Street Target

18% Downside

18% Upside

50% Upside

The latest public price target was made on Apr 11, 2024 by Liisa Bayko from Evercore ISI , who expects VRTX stock to rise by 9% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Liisa Bayko Evercore ISI	438 USD Upside 9%	3 weeks ago Apr 11, 2024	Evercore ISI Upgrades Vertex (VRTX) to Outperform StreetInsider
Andrew Fein H.C. Wainwright	462 USD Upside 15%	3 weeks ago Apr 11, 2024	Vertex Pharmaceuticals price target raised to $462 from $457 at H.C. Wainwright TheFly
Unknown Analyst Morgan Stanley	285 USD Downside 29%	1 year ago Feb 8, 2023	Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $285 Benzinga
Unknown Analyst Leerink Partners	365 USD Downside 9%	1 year ago Feb 8, 2023	SVB Leerink Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $365 Benzinga
Unknown Analyst H.C. Wainwright	326 USD Downside 19%	1 year ago Feb 8, 2023	HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $326 Benzinga

Price Target	438 USD
Upside/Downside	9%

Price Target	462 USD
Upside/Downside	15%

Price Target	285 USD
Upside/Downside	29%

Price Target	365 USD
Upside/Downside	9%

Price Target	326 USD
Upside/Downside	19%

Moderna Inc

8% Upside

Precision BioSciences Inc

220% Upside

Alnylam Pharmaceuticals Inc

49% Upside

Shanghai MicuRx Pharmaceutical Co Ltd

70% Upside

Moderna Inc

8% Upside

Precision BioSciences Inc

220% Upside

Alnylam Pharmaceuticals Inc

49% Upside

Shanghai MicuRx Pharmaceutical Co Ltd

70% Upside

Cyclo Therapeutics Inc

123% Upside

Tango Therapeutics Inc

136% Upside

Centessa Pharmaceuticals PLC

46% Upside

Nykode Therapeutics ASA

189% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 33%. The projected CAGR for the next 3 years is 10%.

33%

10%

-2%

What are analyst estimates?

Operating Income
Forecast

The compound annual growth rate of Vertex Pharmaceuticals Inc's operating income for the next 3 years is 17%.

N/A

17%

-23%

What are analyst estimates?

Net Income
Forecast

The compound annual growth rate of Vertex Pharmaceuticals Inc's net income for the next 3 years is 14%.

N/A

14%

-8%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for VRTX is 474.73 USD with a low forecast of 328.25 USD and a high forecast of 602.7 USD.

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 33%. The projected CAGR for the next 3 years is 10%.

The compound annual growth rate of Vertex Pharmaceuticals Inc's operating income for the next 3 years is 17%.

The compound annual growth rate of Vertex Pharmaceuticals Inc's net income for the next 3 years is 14%.

Join more than 134,500+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.